Malignant Gastric Neoplasm

In this study, real-time quantitative RT-PCR assays were used in 66 pairs of cancerous and matched adjacent normal tissues. In 43 of those pairs, the expression level of ARID1A was significantly lower… (full text at CIViC)

PMID 22808142 · Wang et al., 2012 · Open in CIViC

Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study).

PMID 24841718 · Kubota et al., 2014 · Open in CIViC

This double-blind, randomized, placebo-controlled, phase 3 study (GOLD) recruited Asian patients with advanced gastric cancer that had progressed after first-line chemotherapy. Patients were randomly … (full text at CIViC)

PMID 29103871 · Bang et al., 2017 · Open in CIViC

46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations. Overall survival rate of BCOR positive cases were significantly better than BCOR negative c… (full text at CIViC)

PMID 27313181 · Rokutan et al., 2016 · Open in CIViC

Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.

PMID 10547574 · Takano et al., 1999 · Open in CIViC

Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.

PMID 10547574 · Takano et al., 1999 · Open in CIViC

Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.

PMID 10547574 ·

CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.

PMID 14612939 · Oshimo et al., 2003 · Open in CIViC

CCNE1 amplification has been found in 11–12% of gastric cancers and recent studies have shown that CCNE1 amplification is significantly associated with liver metastasis in a TP53-mutated gastric cance… (full text at CIViC)

PMID 31178228 · Kim et al., 2019 · Open in CIViC

Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.

PMID 10224221 · Donnellan et al., 1999 · Open in CIViC

Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.

PMID 10224221 · Donnellan et al., 1999 · Open in CIViC

465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous … (full text at CIViC)

PMID 27009855 · Böger et al., 2016 · Open in CIViC

In a multivariate analysis from a clinical study including 123 resected primary gastric cancer, CD44s expression at invasive tumor front correlates with a decrease in survival (p< 0.0001). Moreover CD… (full text at CIViC)

PMID 27931044 · Kodama et al., 2017 · Open in CIViC

In a meta-analysis including 4 studies with a total of 629 patients, CD44v6 expression is significantly correlated with a decrease in OS (HR 1.76, 95% IC: 1.30 to 2.39). One study that affects heterog… (full text at CIViC)

PMID 27977599 · Lu et al., 2016 · Open in CIViC

In an in vitro study, CD44v6 knockdown or deletion of exon 11 (v6 specific) had an decrease in cell survival compared to mock cells treated with scramble siRNA when treated with cisplatin or 5-fluorou… (full text at CIViC)

PMID 32842638 · Lobo et al., 2020 · Open in CIViC

285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles. CDH1 mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognos… (full text at CIViC)

PMID 27313181 · Rokutan et al., 2016 · Open in CIViC

In a TCGA study of 295 primary gastric adenocarcinomas, fresh frozen tumors underwent several molecular techniques copy number arrays, exome sequencing, RNA sequencing, and in a subset whole genome se… (full text at CIViC)

PMID 25079317 · 2014 · Open in CIViC

In the phase 3 GLOW trial (NCT03653507), 507 patients with CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma were randomized 1:1 to receive either zolbetuximab combined with CAPOX … (full text at CIViC)

PMID 37524953 · Shah et al., 2023 · Open in CIViC

In the phase 3 SPOTLIGHT trial (NCT03504397), 565 patients with gastroesophageal junction adenocarcinoma were randomized to receive either zolbetuximab combined with mFOLFOX6 (n=283) or placebo with m… (full text at CIViC)

PMID 37068504 · Shitara et al., 2023 · Open in CIViC

CRKL amplification is observed in a subset of gastric cancers. MKN74 cells with CRKL amplification were responsive to the dual Src/BCR-ABL kinase inhibitor Dasatinib, likely via the inhibition of CRKL… (full text at CIViC)

PMID 22591714 · Natsume et al., 2012 · Open in CIViC

CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resis… (full text at CIViC)

PMID 20651371 · Xie et al., 2010 · Open in CIViC

Expression analysis of multiple cohorts of gastric cancer patients in addition to in vivo selected metastatic cell lines, identified DDR2 as the driver of peritoneal dissemination. Within the Singapor… (full text at CIViC)

PMID 26934957 · Kurashige et al., 2016 · Open in CIViC

High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric … (full text at CIViC)

PMID 21458988 · Mutze et al., 2011 · Open in CIViC

This retrospective analysis of a Phase 2 trial shows significant association between increased EGFR gene copy number (≥ 4.0) and overall survival (OS) in patients with gastric and oesophago-gastric ju… (full text at CIViC)

PMID 22152101 · Luber et al., 2011 · Open in CIViC

A case report of a 49 year old female with gastric signet ring cell carcinoma, in whom a genomic screen of cf tumour DNA revealed an EGFR::SEPT14 fusion at a VAF of 45.3%. The fusion was confirmed by … (full text at CIViC)

PMID 33969073 · Kim et al., 2021 · Open in CIViC

A total of 114 patients with gastric cancer were subject to genomic testing for amplified genes in this retrospective study. There were 4 MET amplifications, 3 EGFR amplifications, and 4 HER2 amplific… (full text at CIViC)

PMID 22042947 · Lennerz et al., 2011 · Open in CIViC

8 gastric cancer cell lines were treated with the MTOR inhibitor everolimus. Cell proliferation was effectively inhibited in 3 cell lines by everolimus. Phosphorylated EIF4EBP1 (T37/46, T70) levels we… (full text at CIViC)

PMID 23340172 · Nishi et al., 2013 · Open in CIViC

Afatinib monotherapy was tested in patient-derived colorectal cancer (M051) mouse xenografts and gastric cancer cell-line (NCI-N87) mouse xenografts. Tumor shrinkage was observed and tumor volume was … (full text at CIViC)

PMID 26296355 · Leto et al., 2015 · Open in CIViC

TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer. Primary endpoint was Overall Survival (… (full text at CIViC)

PMID 24868024 · Satoh et al., 2014 · Open in CIViC

In this phase 3, open-label, randomized controlled trial, 594 patients (584 in the primary analysis) with HER2-positive amplification or overexpression gastric or gastroesophageal junction adenocarcin… (full text at CIViC)

PMID 20728210 · Bang et al., 2010 · Open in CIViC

In a retrospective study of Chinese patients with advanced HER2 positive gastric or gastro-esophageal junction (GEJ) cancer who had progressed on first line trastuzumab, continuation (n = 19) versus … (full text at CIViC)

Open in CIViC

In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q did not show a significant association with resistance to nivolumab-contain… (full text at CIViC)

PMID 40699829 · Suzuki et al., 2025 · Open in CIViC

In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q was associated with reduced response to oxaliplatin-based regimens compared… (full text at CIViC)

PMID 40699829 · Suzuki et al., 2025 · Open in CIViC

FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc.

PMID 26637881 · Schmidt et al., 2015 · Open in CIViC

Among 80 patients, FGFR2 amplification was observed in seven cases (11.5%). Patients with FGFR2 amplification had significantly shorter overall survival (OS) than did those without FGFR2 amplification… (full text at CIViC)

PMID 26254407 · Shoji et al., 2015 · Open in CIViC

Xenograft models of SNU-16 human gastric cancer cell lines with FGFR2 amplifications were treated with JNJ-42756493 (erdafitinib). A dose dependent reduction in tumor volume was observed with treatme… (full text at CIViC)

PMID 28341788 · Perera et al., 2017 · Open in CIViC

In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and containing FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited… (full text at CIViC)

PMID 22238366 · Gozgit et al., 2012 · Open in CIViC